Amryt Predicts $1bn Revenues After Chiasma Acquisition
Buying Mycapssa, Only Approved Oral Acromegaly Therapy
The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.
You may also be interested in...
Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
Amryt's Wings Clipped By Delay For Butterfly Skin Drug Decision
The Irish firm needs to give regulators in the US more information on its epidermolysis bullosa therapy but is confident of address those requests from its "existing data within the time periods required," according to CEO Joe Wiley.
Poolbeg Pharma's Capital-Light Model For New Anti-Infectives Development
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.